NCT07142551 2026-03-11
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04558866 2026-02-12
ExBAT
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06039371 2026-01-14
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
University of Washington
Phase 2 Recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03716739 2025-09-23
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06922318 2025-09-17
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03554317 2024-02-20
COMBAT-CRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04424654 2022-08-03
PSMA-BAT
Hospital Sirio-Libanes
Phase 2 Completed
NCT02090114 2022-06-27
Restore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01750398 2016-12-05
BAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed